197 related articles for article (PubMed ID: 36246186)
1. Incidence and Prevalence of Neovascular Age-Related Macular Degeneration in France between 2008 and 2018: The LANDSCAPE Study.
Creuzot-Garcher CP; Srour M; Baudin F; Daien V; Dot C; Nghiem-Buffet S; Girmens JF; Coulombel N; Ponthieux A; Delcourt C
Ophthalmol Sci; 2022 Mar; 2(1):100114. PubMed ID: 36246186
[TBL] [Abstract][Full Text] [Related]
2. Management of Neovascular Age-Related Macular Degeneration Treatment in France from 2008-2018: The Nationwide LANDSCAPE Study.
Creuzot Garcher CP; Srour M; Baudin F; Dot C; Nghiem-Buffet S; Girmens JF; Collin C; Ponthieux A; Delcourt C
Ophthalmol Ther; 2023 Oct; 12(5):2687-2701. PubMed ID: 37531029
[TBL] [Abstract][Full Text] [Related]
3. Real-life management of neovascular age-related macular degeneration (nAMD) in France: a nationwide observational study using retrospective claims data.
Korobelnik JF; Delcourt C; Creuzot-Garcher C; Melaine A; Chassetuillier J; Lejeune A; Bénard S; Dupont-Benjamin L
J Med Econ; 2021; 24(1):1087-1097. PubMed ID: 34420480
[TBL] [Abstract][Full Text] [Related]
4. Incidence and prevalence of neovascular age-related macular degeneration: 15-year epidemiological study in a population-based cohort in Finland.
Korva-Gurung I; Kubin AM; Ohtonen P; Hautala N
Ann Med; 2023 Dec; 55(1):2222545. PubMed ID: 37306515
[TBL] [Abstract][Full Text] [Related]
5. The Patient Voice in Neovascular Age-Related Macular Degeneration: Findings from a Qualitative Study.
Talks SJ; Daien V; Mitchell P; Aslam T; Barratt J; Biberger A; Lamoureux EL; Hirst C; Sylvanowicz M; Finger RP
Ophthalmol Ther; 2023 Feb; 12(1):561-575. PubMed ID: 36525220
[TBL] [Abstract][Full Text] [Related]
6. The Effect of Blue-Light Filtering Intraocular Lenses on the Development and Progression of Neovascular Age-Related Macular Degeneration.
Achiron A; Elbaz U; Hecht I; Spierer O; Einan-Lifshitz A; Karesvuo P; Laine I; Tuuminen R
Ophthalmology; 2021 Mar; 128(3):410-416. PubMed ID: 32717342
[TBL] [Abstract][Full Text] [Related]
7. Incidence of Macular Atrophy after Untreated Neovascular Age-Related Macular Degeneration: Age-Related Eye Disease Study Report 40.
Christakis PG; Agrón E; Klein ML; Clemons TE; Campbell JP; Ferris FL; Chew EY; Keenan TD;
Ophthalmology; 2020 Jun; 127(6):784-792. PubMed ID: 31899035
[TBL] [Abstract][Full Text] [Related]
8. Inflammatory Factors of Macular Atrophy in Eyes With Neovascular Age-Related Macular Degeneration Treated With Aflibercept.
Sato T; Enoki T; Karasawa Y; Someya H; Taguchi M; Harimoto K; Takayama K; Kanda T; Ito M; Takeuchi M
Front Immunol; 2021; 12():738521. PubMed ID: 34721402
[TBL] [Abstract][Full Text] [Related]
9. Anti-vascular endothelial growth factor in neovascular age-related macular degeneration - a systematic review of the impact of anti-VEGF on patient outcomes and healthcare systems.
Finger RP; Daien V; Eldem BM; Talks JS; Korobelnik JF; Mitchell P; Sakamoto T; Wong TY; Pantiri K; Carrasco J
BMC Ophthalmol; 2020 Jul; 20(1):294. PubMed ID: 32680477
[TBL] [Abstract][Full Text] [Related]
10. Macular Atrophy Incidence and Progression in Eyes with Neovascular Age-Related Macular Degeneration Treated with Vascular Endothelial Growth Factor Inhibitors Using a Treat-and-Extend or a Pro Re Nata Regimen: Four-Year Results of the MANEX Study.
Spooner KL; Fraser-Bell S; Cozzi M; Staurenghi G; Invernizzi A; Monteduro D; Munk MR; Hong T; Chang AA
Ophthalmology; 2020 Dec; 127(12):1663-1673. PubMed ID: 32544561
[TBL] [Abstract][Full Text] [Related]
11. Real-World Effectiveness and Real-World Cost-Effectiveness of Intravitreal Aflibercept and Intravitreal Ranibizumab in Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Real-World Studies.
Carrasco J; Pietsch GA; Nicolas MP; Koerber C; Bennison C; Yoon J
Adv Ther; 2020 Jan; 37(1):300-315. PubMed ID: 31728825
[TBL] [Abstract][Full Text] [Related]
12. Prophylactic Ranibizumab to Prevent Neovascular Age-Related Macular Degeneration in Vulnerable Fellow Eyes: A Randomized Clinical Trial.
Chan CK; Lalezary M; Abraham P; Elman M; Beaulieu WT; Lin SG; Khurana RN; Bansal AS; Wieland MR; Palmer JD; Chang LK; Lujan BJ; Yiu G;
Ophthalmol Retina; 2022 Jun; 6(6):484-494. PubMed ID: 35121216
[TBL] [Abstract][Full Text] [Related]
13. Longer-Term Anti-VEGF Therapy Outcomes in Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema, and Vein Occlusion-Related Macular Edema: Clinical Outcomes in 130 247 Eyes.
Ciulla TA; Hussain RM; Taraborelli D; Pollack JS; Williams DF
Ophthalmol Retina; 2022 Sep; 6(9):796-806. PubMed ID: 35381391
[TBL] [Abstract][Full Text] [Related]
14. Pseudodrusen and Incidence of Late Age-Related Macular Degeneration in Fellow Eyes in the Comparison of Age-Related Macular Degeneration Treatments Trials.
Zhou Q; Daniel E; Maguire MG; Grunwald JE; Martin ER; Martin DF; Ying GS;
Ophthalmology; 2016 Jul; 123(7):1530-40. PubMed ID: 27040149
[TBL] [Abstract][Full Text] [Related]
15. Prevalence and incidence of blindness and other degrees of sight impairment in patients treated for neovascular age-related macular degeneration in a well-defined region of the United Kingdom.
Buckle M; Lee A; Mohamed Q; Fletcher E; Sallam A; Healy R; Stratton I; Tufail A; Johnston RL
Eye (Lond); 2015 Mar; 29(3):403-8. PubMed ID: 25592123
[TBL] [Abstract][Full Text] [Related]
16. Twelve-month outcomes of intra-vitreal anti-VEGF agents for treatment-naïve neovascular age-related macular degeneration eyes: French data from the fight for retinal blindness!
Lestable L; Gabrielle PH; Bron AM; Nguyen P; Creuzot-Garcher C
J Fr Ophtalmol; 2020 Oct; 43(8):761-769. PubMed ID: 32622633
[TBL] [Abstract][Full Text] [Related]
17. Incidence and Clinical Practice of Exudative Age-related Macular Degeneration: A Nationwide Population-Based Cohort Study.
Kido A; Miyake M; Tamura H; Hiragi S; Kimura T; Yoshida S; Takeuchi M; Ohtera S; Takahashi A; Ooto S; Kawakami K; Kuroda T; Tsujikawa A
Ophthalmol Sci; 2022 Jun; 2(2):100125. PubMed ID: 36249688
[TBL] [Abstract][Full Text] [Related]
18. VEGF Inhibition Associates With Decreased Risk of Mortality in Patients With Neovascular Age-related Macular Degeneration.
Thinggaard BS; Frederiksen K; Subhi Y; Möller S; Sørensen TL; Kawasaki R; Grauslund J; Stokholm L
Ophthalmol Sci; 2024; 4(3):100446. PubMed ID: 38313400
[TBL] [Abstract][Full Text] [Related]
19. Verteporfin photodynamic therapy for neovascular age-related macular degeneration: cohort study for the UK.
Reeves BC; Harding SP; Langham J; Grieve R; Tomlin K; Walker J; Guerriero C; Carpenter J; Patton WP; Muldrew KA; Peto T; Chakravarthy U
Health Technol Assess; 2012; 16(6):i-xii, 1-200. PubMed ID: 22348600
[TBL] [Abstract][Full Text] [Related]
20. Impact of Sub-Retinal Fluid on the Long-Term Incidence of Macular Atrophy in Neovascular Age-related Macular Degeneration under Treat & Extend Anti-Vascular Endothelial Growth Factor Inhibitors.
Siedlecki J; Fischer C; Schworm B; Kreutzer TC; Luft N; Kortuem KU; Schumann RG; Wolf A; Priglinger SG
Sci Rep; 2020 May; 10(1):8036. PubMed ID: 32415240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
